Northway WH, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline membrane disease. Bronchopulonary dysplasia. N Engl J Med. 1967;276:357–68.
Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001;163:1723–9.
Jobe AH. The new BPD: an arrest of lung development. Pediatr Res. 1999;46:641–3.
Baraldi E, Filippone M. Chronic lung disease after premature birth. N Engl J Med. 2007;357(19):1946–55.
Hussain AN, Siddiqui NH, Stocker JT. Pathology of arrested acinar development in postsurfactant BPD. Hum Pathol. 1998;29:710–7.
McEvoy C, Jain L, Schmidt B, Abman SH, Bancalari E, Aschner J. Bronchopulmonary dysplasia: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases. Ann Am Thorac Soc. 2014;Suppl 3:S146–53.
Stoll BJ, Hansen NI, Bell EF, et al. Trends in care practices, morbidity and mortality of extremely preterm neonates. JAMA. 2015;314:1039–51.
Wong PM, Lees AN, Louw J, et al. Emphysema in young adult survivors of moderate-to-severe bronchopulmonary dysplasia. Eur Respir J. 2008;32(2):321–8.
Hislop AA, Haworth SG. Pulmonary vascular damage and the development of cor pulmonale following hyaline membrane disease. Pediatr Pulmonol. 1990;9:152–161.
Bush A, Busst CM, Knight WB, Hislop AA, Haworth SG, Shinebourne EA. Changes in the pulmonary circulation in BPD. Arch Dis Child. 1990;65:739–45.
Fouron JC, Le Guennec JC, Villemant D, et al. Value of echocardiography in assessing the outcome of bronchopulmonary dysplasia of the newborn. Pediatrics. 1980;65(3):529–35.
Abman SH. Pulmonary hypertension in chronic lung disease of infancy. Pathogenesis, pathophysiology and treatment. In: Bland RD, Coalson JJ, editors. Chronic lung disease of infancy. New York: Marcel Dekker; 2000. p. 619–68.
Mourani PM, Sontag MK, Younoszai A, Miller JI, Kinsella JP, Baker CD, Poindexter BB, Ingram DA, Abman SH. Early pulmonary vascular disease in preterm infants at risk for BPD. Am J Respir Crit Care Med. 2015;191:87–95.
Mirza H, Ziegler J, Ford S, Padbury J, Tucker R, Laptook A. Pulmonary hypertension in preterm infants: prevalence and association with bronchopulmonary dysplasia. J Pediatr. 2014;165(5):909–14.e1.
Khemani E, McElhinney DB, Rhein L, et al. Pulmonary artery hypertension in formerly premature infants with bronchopulmonary dysplasia: clinical features and outcomes in the surfactant era. Pediatrics. 2007;120(6):1260–9.
Abman SH, Hansmann G, Archer S, et al. American Heart Association and American Thoracic Society Joint Guidelines for Pediatric Pulmonary Hypertension. Circulation. 2015;132:2037–99.
Stenmark KR, Abman SH. Lung vascular development: implications for the pathogenesis of bronchopulmonary dysplasia. Annu Rev Physiol. 2005;67:623–61.
Thebaud B, Abman SH. Bronchopulmonary dysplasia: where have all the vessels gone? Roles of angiogenic growth factors in chronic lung disease. Am J Respir Crit Care Med. 2007;175(10):978–85.
Bhatt AJ, Pryhuber GS, Huyck H, et al. Disrupted pulmonary vasculature and decreased VEGF, flt-1, and Tie 2 in human infants dying with BPD. Am J Respir Crit Care Med. 2000;164:1971–80.
Lassus P, Turanlahti M, Heikkila P, et al. Pulmonary vascular endothelial growth factor and Flt-1 in fetuses, in acute and chronic lung disease, and in persistent pulmonary hypertension of the newborn. Am J Respir Crit Care Med. 2001;164(10 Pt 1):1981–7.
De Paepe ME, Mao Q, Powell J, et al. Growth of pulmonary microvasculature in ventilated preterm infants. Am J Respir Crit Care Med. 2006;173(2):204–11.
Mourani PM, Abman SH. Pulmonary vascular disease in BPD: physiology, diagnosis and treatment. In: Abman SH, editor. Bronchopulmonary dysplasia. New York: Informa; 2010. p. 347–63.
Jakkula M, Le Cras TD, Gebb S, et al. Inhibition of angiogenesis decreases alveolarization in the developing rat lung. Am J Physiol Lung Cell Mol Physiol. 2000;279:L600–7.
Abman SH. BPD: a vascular hypothesis. Am J Respir Crit Care Med. 2001;164:1755–6.
Abman SH. Impaired vascular endothelial growth factor signaling in the pathogenesis of neonatal pulmonary vascular disease. Adv Exp Med Biol. 2010;661:323–35.
Balinotti JE, Chakr VC, Tiller C, et al. Growth of lung parenchyma in infants and toddlers with chronic lung disease of infancy. Am J Respir Crit Care Med. 2010;181(10):1093–7.
Hansen AR, Barnes CM, Folkman J, McElrath TF. Maternal preeclampsia predicts the development of bronchopulmonary dysplasia. J Pediatr. 2010;156(4):532–6.
Foidart JM, Schaaps JP, Chantraine F, Munaut C, Lorquet S. Dysregulation of anti-angiogenic agents (sFlt-1, PLGF, and sEndoglin) in preeclampsia – a step forward but not the definitive answer. J Reprod Immunol. 2009;82(2):106–11.
Tang JR, Karumanchi SA, Seedorf G, Markham N, Abman SH. Excess soluble vascular endothelial growth factor receptor-1 in amniotic fluid impairs lung growth in rats: linking preeclampsia with bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol. 2012;302(1):L36–46.
Li F, Hagaman JR, Kim HS, et al. eNOS deficiency acts through endothelin to aggravate sFlt-1-induced pre-eclampsia-like phenotype. J Am Soc Nephrol. 2012;23(4):652–60.
Rozance PJ, Seedorf GJ, Brown A, et al. Intrauterine growth restriction decreases pulmonary alveolar and vessel growth and causes pulmonary artery endothelial cell dysfunction in vitro in fetal sheep. Am J Physiol Lung Cell Mol Physiol. 2011;301(6):L860–71.
Check J, Gotteiner N, Liu X, et al. Fetal growth restriction and pulmonary hypertension in premature infants with bronchopulmonary dysplasia. J Perinatol. 2013;33:553–7.
Evans NJ, Archer LNJ. Doppler assessment of pulmonary artery pressure during recovery from hyaline membrane disease. Arch Dis Child. 1991;66:802–4.
Subhedar NV, Shaw NJ. Changes in pulmonary arterial pressure in preterm infants with chronic lung disease. Arch Dis Child. 2000;82:F243–7.
Czernik C, Rhode S, Metze B, Schmalisch G, Buhrer C. Persistently elevated right ventricular index of myocardial performance in preterm infants with incipient bronchopulmonary dysplasia. PLoS One. 2012;7(6):e38352.
Skinner JR, Boys RJ, Hunter S, Hey EN. Pulmonary and systemic arterial pressure in hyaline membrane disease. Arch Dis Child. 1992;67(4 Spec No):366–73.
Abman SH, Wolfe RR, Accurso FJ, Koops BL, Wiggins JW. Pulmonary vascular response to to oxygen in infants with severe BPD. Pediatrics. 1985;75:80–4.
Mourani P, Ivy DD, Gao D, Abman SH. Pulmonary vascular effects of inhaled NO and oxygen tension in older children and adolescents with bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2004;170:1006–13.
Galambos C, Sims-Lucas S, Abman SH. Histologic evidence of intrapulmonary arteriovenous shunt vessels in premature infants with severe bpd. Ann Am Thorac Soc. 2013;10:474–81.
Abman SH, Schaffer MS, Wiggins JW, et al. Pulmonary vascular extraction of circulating norepinephrine in infants with BPD. Pediatr Pulmonol. 1987;3:386–91.
An HS, Bae EJ, Kim GB, et al. Pulmonary hypertension in preterm infants with BPD. Korean Circ J. 2010;40:131–6.
Slaughter JR, Pakradhi T, Lones DE et al. Echocardiographic detection of pulmonary hypertension in extremely low birth weight infants with BPD requiring prolonged positive pressure ventilation. J Perinatol. 2011;31:1–6.
Currie PJ, Seward JB, Chan KL, et al. Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler-catheterization study in 127 patients. J Am Coll Cardiol. 1985;6(4):750–6.
Mourani PM, Sontag MK, Younoszai A, et al. Clinical utility of echocardiography for the diagnosis and management of pulmonary vascular disease in young children with chronic lung disease. Pediatrics. 2008;121(2):317.
Drossner DM, Kim DW, Maher KO, et al. Pulmonary vein stenosis: prematurity and associated conditions. Pediatrics. 2008;122:e656–61.
Mourani PM, Fagan T, Ivy DD, Rosenberg A, Abman SH. Left ventricular diastolic dysfunction in bronchopulmonary dysplasia. J Pediatr. 2008;152:291–3.
Del Cerro MJ, Sabate-Rotes A, Carton A, et al. Pulmonary hypertension in BPD: clinical findings, cardiovascular abnormalities and outcomes. Pediatr Pulmonol. 2014;49:49–59.
Banks BA, Seri I, Ischiropoulos H, et al. Changes in oxygenation with inhaled nitric oxide in severe bronchopulmonary dysplasia. Pediatrics. 1999;103(3):610–8.
Baquero H, Soliz A, Neira F, et al. Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: a pilot randomized blinded study. Pediatrics. 2006;117(4):1077–83.
Humpl T, Reyes JT, Holtby H, et al. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study. Circulation. 2005;111(24):3274–80.
Mourani PM, Sontag MK, Lui G, et al. Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. J Pediatr. 2008;121:317–25.
Rosenzweig EB, Ivy DD, Widlitz A, et al. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol. 2005;46(4):697–704.
Brownlee JR, Beekman RH, Rosenthal A. Acute hemodynamic effects of nifedipine in infants with bronchopulmonary dysplasia and pulmonary hypertension. Pediatr Res. 1988;24(2):186–90.
Johnson CE, Beekman RH, Kostyshak DA, et al. Pharmacokinetics and pharmacodynamics of nifedipine in children with bronchopulmonary dysplasia and pulmonary hypertension. Pediatr Res. 1991;29(5):500–3.
Ferdman DJ, Rosenzweig EB, Zuckerman WA, Krishnan U. Subcutaneous treprostinil for pulmonary hypertension in chronic lung disease of infancy. Pediatrics. 2014;134:e274–8.